This represents the latest in a series of safety concerns associated with the Impella platform. The FDA said it is still reviewing the matter and will keep the public informed as new details become available.
Cardiovascular disease is already the No. 1 killer among women—and new projections from the American Heart Association suggest things are going to get much worse. There are certain things that clinicians and patients can do, however, to help reverse this trend and save countless lives.
“These findings underscore the urgency for sustainable practices within neurointerventional care to reduce both environmental footprints and costs,” experts write in Radiology.
In the new role, Michael DeLeo, MD, MBA, will shape the company's physician management infrastructure, providing radiology services while leading strategic and operational initiatives.
Sycamore Partners took over the struggling retail pharmacy chain roughly six months ago, and the Private Equity Stakeholder Project fears early staffing cuts and store closures could spell trouble for the long-term health of the newly restructured business.
The facility in question was not revealed in a video posted on Instagram, where social media star Joshua Cauldwell-Clarke read the letter aloud and asked healthcare workers to please respect the rights of patients.
UnitedHealthcare now requires patients enrolled in certain Medicare Advantage plans to receive a PCP referral before seeing a cardiologist. On May 1, the insurer will start denying all claims that do not include the necessary referral. UnitedHealthcare argues that "stronger PCP engagement" is good for patient care, but many stakeholders disagree.
In fact, researchers wrote, TAVR and SAVR were linked to comparable long-term outcomes for heart patients who have previously been exposed to mediastinal radiation.
The introduction of a 3D pediatric transesophegeal echo probe is having a major impact on how these pediatric congenital heart patients are being treated.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
